MediciNova completes Phase 2 trial last patient visit for MN-001 in NAFLD, hypertriglyceridemia linked to type 2 diabetes

MediciNova, Inc.

MediciNova, Inc.

MNOV

0.00
  • MediciNova completed last patient last visit in a Phase 2 trial of MN-001 for high triglycerides and fatty liver disease tied to type 2 diabetes.
  • Top-line results have not been presented; data are expected in Q3 2026.
  • The study is designed to assess whether MN-001 can reduce liver fat and improve triglyceride levels versus placebo.
  • The readout could shape next-step development plans for MN-001 in metabolic liver disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605261900PRIMZONEFULLFEED9726532) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.